NCT05596045

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

A Phase Ib, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 Tablets in Mild or Moderate COVID-19 Patients

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Ascletis Pharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 tablets in mild or moderate COVID-19 subjects.

Conditions

• SARS CoV 2 Infection

Interventions

Type	Name	Description
DRUG	ASC10	Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
DRUG	Placebo	Participants will be randomized to receive placebo

Timeline

• Start date: 2022-11-28
• Primary completion: 2023-03-08
• Completion: 2023-10-09
• First posted: 2022-10-27
• Last updated: 2024-11-01

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study